Previous 10 | Next 10 |
Exelixis ( EXEL ) announced that it had obtained FDA approval for its drug cabometyx for previously treated patients with hepatocellular carcinoma (liver cancer). This latest approval expands the market opportunity of this drug in the U.S. market. This is good news on top of previous news ...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued by a bit more than 10% relative to historical avera...
Competition is a rude yet effective motivation .” ― Toba Beta Mid-cap oncology concern Exelixis ( EXEL ) reported Q4 results after the bell on Tuesday. As the company has done for over a year now, quarterly numbers easily beat both top line and bottom line consensus by a g...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
On cue, sell-side analysts have their pom-poms out for Exelixis (NASDAQ: EXEL ) after its Q4 report that included an 84% jump in cabozantinib sales. More news on: Exelixis, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Exelixis, Inc. (EXEL) Q4 2018 Results Earnings Conference Call February 12, 2019, 05:00 PM ET Company Participants Susan Hubbard - EVP-Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - SVP-Commercial Peter Lamb - Chief Scientific Officer...
Gainers: UIS +11.6% . EXEL +6.9% . LSCC +6.6% . IRTC +4.3% . JCOM +3.4% . More news on: Dolby Laboratories, Inc., Unisys Corporation, Exelixis, Inc., Stocks on the move, , Read more ...
Exelixis (NASDAQ: EXEL ) initiates a Phase 1 clinical trial evaluating XL092, its first internally discovered compound to enter the clinic after it resumed drug discovery activities. The first phase will assess safety, tolerability and pharmacokinetics while the dose-escalation phase will ...
Exelixis (NASDAQ: EXEL ) Q4 results ($M): Revenues: 228.6 (+90.3%); cabozantinib sales: 176.2 (+84.1%). More news on: Exelixis, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Exelixis (NASDAQ: EXEL ): Q4 Non-GAAP EPS of $0.37 beats by $0.14 ; GAAP EPS of $1.15 beats by $0.92 . More news on: Exelixis, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...